$1.17
8.95% today
Nasdaq, Apr 04, 10:16 pm CET
ISIN
US98943L1070
Symbol
ZNTL
Sector
Industry

Zentalis Pharmaceuticals Inc Stock price

$1.17
-0.70 37.43% 1M
-2.20 65.28% 6M
-1.86 61.39% YTD
-14.15 92.36% 1Y
-51.08 97.76% 3Y
-23.22 95.20% 5Y
-22.03 94.96% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.12 8.95%
ISIN
US98943L1070
Symbol
ZNTL
Sector
Industry

Key metrics

Market capitalization $92.28m
Enterprise Value $-236.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.38
EV/Sales (TTM) EV/Sales -3.50
P/S ratio (TTM) P/S ratio 1.37
P/B ratio (TTM) P/B ratio 0.27
Revenue (TTM) Revenue $67.43m
EBIT (operating result TTM) EBIT $-187.46m
Free Cash Flow (TTM) Free Cash Flow $-171.08m
Cash position $371.08m
EPS (TTM) EPS $-2.33
P/E forward negative
Short interest 15.05%
Show more

Is Zentalis Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Zentalis Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:

5x Buy
45%
6x Hold
55%

Analyst Opinions

11 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:

Buy
45%
Hold
55%

Financial data from Zentalis Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
67 67
-
100%
- Direct Costs 1.29 1.29
7% 7%
2%
66 66
4,858% 4,858%
98%
- Selling and Administrative Expenses 85 85
37% 37%
125%
- Research and Development Expense 168 168
12% 12%
249%
-186 -186
26% 26%
-276%
- Depreciation and Amortization 1.29 1.29
7% 7%
2%
EBIT (Operating Income) EBIT -187 -187
26% 26%
-278%
Net Profit -166 -166
43% 43%
-246%

In millions USD.

Don't miss a Thing! We will send you all news about Zentalis Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zentalis Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
3 days ago
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock optio...
Neutral
GlobeNewsWire
9 days ago
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC)
Neutral
GlobeNewsWire
10 days ago
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC)
More Zentalis Pharmaceuticals Inc News

Company Profile

Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.

Head office United States
CEO Julia Eastland
Employees 166
Founded 2014
Website www.zentalis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today